RxDoctor Payments Data

Amy Rothstein

Nurse Practitioner · Rockville, MDNPI 1871218115

Payments from drug & device makers

$4,473in general payments, 2019–2025

Across 130 payments — averaging $34.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$728
  • Sumitomo Pharma America, Inc.$685
  • Johnson & Johnson$499
  • Astellas Pharma US Inc$358
  • Bayer$343
  • Pfizer$283
  • plus $2K from 20 others

What the payments were for

  • Speaking & faculty fees$1122%
  • Travel & lodging$2205%
  • Food & beverage$3,92088%
  • Education$2055%
  • Gifts$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,473 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Medicare billing

Part B allowed, 2024
$546,012
Medicare patients
878
Services billed
25,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide13$314,052
GemtesaVibegron43$38,331
MyrbetriqMirabegron37$29,651
Abiraterone Acetate15$29,472
Tamsulosin Hcl221$4,760
Solifenacin Succinate24$2,231
Estradiol22$1,497
Dutasteride14$1,135
Alfuzosin Hcl ErAlfuzosin Hcl38$1,069
Methenamine Hippurate13$838
Finasteride47$609
Ciprofloxacin Hcl23$176
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$176
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim41$170
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav19$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$358$343,70350 claims
Sumitomo Pharma America, Inc.Gemtesa$685$38,33143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →